# Genentech

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/genentech/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | biotech company |
| OpenAlex ID | https://openalex.org/F4320332193 |
| ROR ID | https://ror.org/04gndp242 |
| Works | 30,858 |

## Funder papers

- [Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity](https://scholariq.org/papers/effect-of-continued-weekly-subcutaneous-semaglutide-vs-placebo-on-weight-loss/)
- [2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis](https://scholariq.org/papers/2019-update-of-the-joint-european-league-against-rheumatism-and-european-renal/)
- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes](https://scholariq.org/papers/concurrent-rb1-and-tp53-alterations-define-a-subset-of-egfr-mutant-lung-cancers/)
- [Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study](https://scholariq.org/papers/durvalumab-in-combination-with-olaparib-in-patients-with-relapsed-sclc-results/)
- [Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/niraparib-first-line-maintenance-therapy-in-patients-with-newly-diagnosed/)
- [Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers](https://scholariq.org/papers/molecular-biomarkers-of-disease-outcomes-and-mechanisms-of-acquired-resistance/)
- [Atopic Dermatitis in US Adults: From Population to Health Care Utilization](https://scholariq.org/papers/atopic-dermatitis-in-us-adults-from-population-to-health-care-utilization/)
- [Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA–Associated Vasculitis](https://scholariq.org/papers/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the-2/)
- [Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome](https://scholariq.org/papers/continuous-b-cell-depletion-in-frequently-relapsing-steroid-dependent-and/)
- [Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/efficacy-and-safety-of-niraparib-in-patients-aged-65-years-and-older-with/)
- [Prophylaxis against intraocular pressure spikes following uncomplicated phacoemulsification: a systematic-review and meta-analysis](https://scholariq.org/papers/prophylaxis-against-intraocular-pressure-spikes-following-uncomplicated/)
- [The Impact of the <scp>COVID</scp>‐19 Pandemic on Care Partners of People with Parkinson's Disease](https://scholariq.org/papers/the-impact-of-the-scp-covid-scp-19-pandemic-on-care-partners-of-people-with/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.